thiopental 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
hypnotics, barbituric acid derivatives	2633	76-75-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pentothal thiopental sodium thiopental thiomebumal thionembutal pentothiobarbital	A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. Molecular weight: 242.34 Formula: C11H18N2O2S CLOGP: 2.98 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 58.20 ALOGS: -3.78 ROTB: 4 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pentothal
thiopental sodium
thiopental
thiomebumal
thionembutal
pentothiobarbital

A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.

Molecular weight: 242.34
Formula: C11H18N2O2S
CLOGP: 2.98
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 58.20
ALOGS: -3.78
ROTB: 4

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	20.63 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.14 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
None	FDA	ABBOTT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	178.98	57.04	50	2135	15183	63471654
Diabetes insipidus	162.06	57.04	33	2152	2592	63484245
Renal ischaemia	144.26	57.04	24	2161	609	63486228
PCO2 increased	128.17	57.04	24	2161	1215	63485622
Breast cancer recurrent	124.13	57.04	29	2156	4312	63482525
Foetal death	119.62	57.04	34	2151	10946	63475891
PO2 increased	116.53	57.04	21	2164	858	63485979
Blood pH decreased	110.54	57.04	24	2161	2563	63484274
Blood bicarbonate decreased	107.48	57.04	24	2161	2917	63483920
Left ventricular dysfunction	103.53	57.04	31	2154	11957	63474880
Oxygen saturation abnormal	103.12	57.04	24	2161	3505	63483332
Blood magnesium decreased	75.79	57.04	25	2160	13173	63473664
Exposure during pregnancy	74.39	57.04	53	2132	155494	63331343
Maternal exposure during pregnancy	72.39	57.04	60	2125	220002	63266835
Hypotension	70.91	57.04	65	2120	272539	63214298
Electroencephalogram abnormal	61.64	57.04	16	2169	3656	63483181

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	123.91	49.17	125	1461	456626	34498719
Status epilepticus	122.45	49.17	38	1548	12576	34942769
Intensive care unit acquired weakness	107.51	49.17	21	1565	1006	34954339
Multiple-drug resistance	82.56	49.17	23	1563	5216	34950129
Diabetes insipidus	60.87	49.17	16	1570	2912	34952433
Hepatitis fulminant	55.19	49.17	16	1570	4174	34951171
Off label use	53.63	49.17	79	1507	419445	34535900

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	242.95	41.66	76	3659	24965	79715688
Diabetes insipidus	211.13	41.66	49	3686	5188	79735465
Drug ineffective	157.79	41.66	220	3515	1080693	78659960
Intensive care unit acquired weakness	150.14	41.66	31	3704	1902	79738751
Renal ischaemia	122.27	41.66	24	3711	1138	79739515
Foetal death	119.61	41.66	34	3701	8010	79732643
PCO2 increased	111.27	41.66	24	3711	1816	79738837
Multiple-drug resistance	107.78	41.66	32	3703	8776	79731877
PO2 increased	97.64	41.66	21	3714	1567	79739086
Blood pH decreased	93.55	41.66	25	3710	4686	79735967
Blood bicarbonate decreased	91.15	41.66	25	3710	5166	79735487
Oxygen saturation abnormal	89.50	41.66	24	3711	4558	79736095
Left ventricular dysfunction	79.51	41.66	31	3704	19330	79721323
Maternal exposure during pregnancy	78.87	41.66	59	3676	136479	79604174
Exposure during pregnancy	72.85	41.66	50	3685	101082	79639571
Malabsorption	64.69	41.66	19	3716	5013	79735640
Blood magnesium decreased	62.75	41.66	25	3710	16487	79724166
Off label use	57.77	41.66	129	3606	907086	78833567
Electroencephalogram abnormal	54.72	41.66	17	3718	5417	79735236
Multiple organ dysfunction syndrome	54.36	41.66	45	3690	120201	79620452
Hepatitis fulminant	49.88	41.66	17	3718	7245	79733408
Hypotension	45.49	41.66	77	3658	440240	79300413
Blood calcium decreased	44.26	41.66	24	3711	31795	79708858
Seizure	43.95	41.66	49	3686	188785	79551868
Clonus	43.04	41.66	15	3720	6825	79733828
Partial seizures	42.68	41.66	16	3719	8962	79731691
Hyperthermia malignant	41.86	41.66	12	3723	2905	79737748

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01AF03	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Barbiturates, plain
ATC	N05CA19	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Barbiturates, plain
MeSH PA	D000777	Anesthetics
MeSH PA	D018686	Anesthetics, Intravenous
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:38877	intravenous anesthetics
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:78298	environmental contaminants
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Benign intracranial hypertension	indication	68267002	DOID:11459
Epilepsy	indication	84757009	DOID:1826
Narcoanalysis	indication	302683009
Cerebral ischemia	off-label use	287731003
Hypoxia of brain	off-label use	389088001
Chronic disease of respiratory system	contraindication	17097001
Shock	contraindication	27942005
Myxedema	contraindication	43153006	DOID:11634
Uremia	contraindication	44730006	DOID:4676
Low blood pressure	contraindication	45007003
Variegate porphyria	contraindication	58275005	DOID:4346
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Acute disease of cardiovascular system	contraindication	128487001
Asthma	contraindication	195967001	DOID:2841
Acute intermittent porphyria	contraindication	234422006	DOID:3890
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Primary adrenocortical insufficiency	contraindication	373662000

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Anesthesia in short to moderately long surgical procedures	Indication
Dogs	Anesthesia in short to moderately long surgical procedures	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Combuthal Powder	Bimeda Animal Health Limited	2
Sodium Thiopental	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.46	acidic
pKa2	11.46	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR			WOMBAT-PK	CHEMBL
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		IC50	4.53	CHEMBL
Potassium voltage-gated channel subfamily C member 4	Ion channel		KCNC4_RAT	GATING INHIBITOR	IC50	4	IUPHAR

External reference:

ID	Source
4018713	VUID
N0000179744	NUI
D00714	KEGG_DRUG
71-73-8	SECONDARY_CAS_RN
4018713	VANDF
4019945	VANDF
C0039925	UMLSCUI
CHEBI:102166	CHEBI
EDP	PDB_CHEM_ID
CHEMBL441	ChEMBL_ID
DB00599	DRUGBANK_ID
CHEMBL738	ChEMBL_ID
D013874	MESH_DESCRIPTOR_UI
3000715	PUBCHEM_CID
2579	IUPHAR_LIGAND_ID
JI8Z5M7NA3	UNII
10493	RXNORM
2118	MMSL
2227	MMSL
5570	MMSL
d00388	MMSL
001398	NDDF
004578	NDDF
349829005	SNOMEDCT_US
387448009	SNOMEDCT_US
412605006	SNOMEDCT_US
433	INN_ID

Pharmaceutical products:

None